Report Description

Global antiviral drugs market showed an impressive growth in the historical years, and it is expected to show its exponential growth in the forecast years, 2023-2027 with anticipated CAGR. The market growth can be reasoned with the rising number of infectious diseases in the world. Moreover, government and private funding for the ongoing research and development of the therapeutics, and drugs against these infectious diseases is also responsible for the growth of the global antiviral drugs market in the upcoming five years.

Furthermore, the recent outbreak of COVID-19 virus is a huge turning point for the antiviral drugs market. The outbreak caused a mayhem that World Health Organization (WHO) had to declare it a pandemic within four months of its spread. The viral infection has already taken millions of lives worldwide and continues to do so in the absence of cure. Many research institutes have released the vaccines and drugs against the virus but still a 100% cure is still not confirmed against the virus.

Similar infectious diseases like Swine-flu, H1N1 virus infection, etc. created surge in the demand for the antiviral drugs, therefore supporting the growth of the global antiviral drugs market in the next five years.

The global antiviral drugs market is segmented by drug class, indications, route of administration, type, age group, end users, distribution channel, competitional landscape, and regional distribution. Based on drug class, the market is further bifurcated into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, m-RNA synthesis inhibitors, integrase inhibitors, and others.

DNA polymerase inhibitors are the therapeutic drugs that favorably inhibits the DNA polymerase enzyme which is responsible for the multiplication of the genetic material. Reverse transcriptase inhibitors are functional in similar way too. These inhibitors stop reverse transcriptase from performing its function. In case of viral antigens, viruses do not carry DNA. Their genetic material involves RNA, ribonucleic acid.

Reverse transcriptase is responsible for initiating & carrying out the process of translating DNA from RNA and then make RNA to produce more viral protein which causes more infection to the infected human. Reverse transcriptase inhibitors are also anticipated to hold the largest market shares and dominate the market segment on the account of its advantage in averting and slowing down the process of viral infection.

Holding the largest revenue shares of the global antiviral drugs market, a partial list of the market player includes Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., GlaxoSmithKline PLC, Mylan N.V., Cipla Ltd., Laurus Labs Ltd., Micro Labs Ltd., Gilead Sciences, Inc., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Alembic Pharmaceuticals Limited, Novartis AG, Bristol Myers Squibb Company, AstraZeneca Ltd., among others.

The market players are actively involved in the research and development of the antiviral drugs and therapeutics. With the advanced research, the pharmaceutical labs are able to counter act the viral infections that are widely spreading.

Moreover, the ever changing environment and tendency of viral antigens to overcome the drugs and therapeutics effect, demand aggressive and consistent research for the advanced and effective drugs. New market players can adopt the very research for their market establishment. Other strategic recommendation may include partnerships and acquisitions.

Objective of the Study:

  • To analyze the historical growth of the market size of global anti-viral drugs market from 2017 to 2020.
  • To estimate and forecast the market size of global anti-viral drugs market from 2021 to 2027 and growth rate until 2027. 
  • To classify and forecast global anti-viral drugs market based on drug class, indication, route of administration, type, age group, end-user, distribution channel, regional distribution, and competitional landscape.
  • To identify dominant region or segment in the global anti-viral drugs market.
  • To identify drivers and challenges for global anti-viral drugs market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global anti-viral drugs market.
  • To identify and analyze the profile of leading players operating in global anti-viral drugs market.
  • To identify key sustainable strategies adopted by market players in global anti-viral drugs market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and service providers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the country.

TechSci Research calculated the market size of global anti-viral drugs market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Manufacturers, end users, service providers and other stakeholders
  • Distributers and suppliers of products and other stakeholders
  • Organizations, forums, and alliances related to anti-viral drugs market  
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Attribute

Details

Base Year

2021

Historical Years

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million and CAGR for 2017-2021 and 2022-2027

Report Coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered

  • Drugs Class
  • Indication
  • Route of Administration
  • Type
  • Age Group
  • End User
  • Distribution Channel

Regional Scope

North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa

Country Scope

United States; Canada; Mexico; China; India; Japan; Australia; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; Saudi Arabia; UAE; South Africa

Key Companies Profiled

Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., GlaxoSmithKline PLC, Mylan N.V., Cipla Ltd., Laurus Labs Ltd., Micro Labs Ltd., Gilead Sciences, Inc., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Alembic Pharmaceuticals Limited, Novartis AG, Bristol Myers Squibb Company, AstraZeneca Ltd.

Customization Scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, global anti-viral drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Anti-Viral Drugs Market, By Drug Class:
    • DNA Polymerase Inhibitors
    • Reverse Transcriptase Inhibitors
    • Protease Inhibitors
    • m-RNA Synthesis Inhibitors
    • Integrase Inhibitors
    • Others
  • Global Anti-Viral Drugs Market, By Indication:
    • Coronavirus Infection
    • HIV
    • Hepatitis
    • Herpes Simplex Virus
    • Influenza
    • Others
      • Pneumonia
      • Flu  
  • Global Anti-Viral Drugs Market, By Route of Administration:
    • Oral
    • Topical
    • Parenteral
    • Others
  • Global Anti-Viral Drugs Market, By Type:
    • Branded
    • Generic
  • Global Anti-Viral Drugs Market, By Age Group:
    • Pediatric
    • Adult
    • Geriatric
  • Global Anti-Viral Drugs Market, By End User:
    • Hospitals
    • Homecare
    • Specialty Clinics
    • Others
  • Global Anti-Viral Drugs Market, By Distribution Channel:
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Global Anti-Viral Drugs Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
    • South America
      • Brazil
      • Argentina
      • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global anti-viral drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five). 
Global Anti-Viral Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Antiviral Drugs Market

4.    Executive Summary

5.    Voice of Customer

6.    Global Antiviral Drugs Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, m-RNA Synthesis Inhibitors, Integrase Inhibitors, Others)

6.2.2.     By Indication (Coronavirus Infection, HIV, Hepatitis, Herpes Simplex Virus, Influenza, Others (Pneumonia, Flu))

6.2.3.     By Route of Administration (Oral, Topical, Parenteral, Others)

6.2.4.     By Type (Branded, Generic)

6.2.5.     By Age Group (Pediatric, Adult, Geriatric)

6.2.6.     By End-User (Hospitals, Homecare, Specialty Clinics, Others)

6.2.7.     By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

6.2.8.     By Company (2021)

6.2.9.     By Region

6.3.  Product Market Map

7.    Asia-Pacific Antiviral Drugs Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Drug Class

7.2.2.     By Indication

7.2.3.     By Route of Administration

7.2.4.     By Type

7.2.5.     By Age Group

7.2.6.     By End User

7.2.7.     By Distribution Channel

7.2.8.     By Country

7.3.  Asia-Pacific: Country Analysis

7.3.1.     China Antiviral Drugs Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Drug Class

7.3.1.2.2.             By Indication

7.3.1.2.3.             By Route of Administration

7.3.1.2.4.             By Type

7.3.1.2.5.             By Age Group

7.3.1.2.6.             By End User

7.3.1.2.7.             By Distribution Channel

7.3.2.     India Antiviral Drugs Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Drug Class

7.3.2.2.2.             By Indication

7.3.2.2.3.             By Route of Administration

7.3.2.2.4.             By Type

7.3.2.2.5.             By Age Group

7.3.2.2.6.             By End User

7.3.2.2.7.             By Distribution Channel

7.3.3.     Japan Antiviral Drugs Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Drug Class

7.3.3.2.2.             By Indication

7.3.3.2.3.             By Route of Administration

7.3.3.2.4.             By Type

7.3.3.2.5.             By Age Group

7.3.3.2.6.             By End User

7.3.3.2.7.             By Distribution Channel

7.3.4.     South Korea Antiviral Drugs Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Drug Class

7.3.4.2.2.             By Indication

7.3.4.2.3.             By Route of Administration

7.3.4.2.4.             By Type

7.3.4.2.5.             By Age Group

7.3.4.2.6.             By End User

7.3.4.2.7.             By Distribution Channel

7.3.5.     Australia Antiviral Drugs Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Drug Class

7.3.5.2.2.             By Indication

7.3.5.2.3.             By Route of Administration

7.3.5.2.4.             By Type

7.3.5.2.5.             By Age Group

7.3.5.2.6.             By End User

7.3.5.2.7.             By Distribution Channel

8.    Europe Antiviral Drugs Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Drug Class

8.2.2.     By Indication

8.2.3.     By Route of Administration

8.2.4.     By Type

8.2.5.     By Age Group

8.2.6.     By End User

8.2.7.     By Distribution Channel

8.2.8.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Antiviral Drugs Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Drug Class

8.3.1.2.2.             By Indication

8.3.1.2.3.             By Route of Administration

8.3.1.2.4.             By Type

8.3.1.2.5.             By Age Group

8.3.1.2.6.             By End User

8.3.1.2.7.             By Distribution Channel

8.3.2.     Germany Antiviral Drugs Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Drug Class

8.3.2.2.2.             By Indication

8.3.2.2.3.             By Route of Administration

8.3.2.2.4.             By Type

8.3.2.2.5.             By Age Group

8.3.2.2.6.             By End User

8.3.2.2.7.             By Distribution Channel

8.3.3.     United Kingdom Antiviral Drugs Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Drug Class

8.3.3.2.2.             By Indication

8.3.3.2.3.             By Route of Administration

8.3.3.2.4.             By Type

8.3.3.2.5.             By Age Group

8.3.3.2.6.             By End User

8.3.3.2.7.             By Distribution Channel

8.3.4.     Italy Antiviral Drugs Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Drug Class

8.3.4.2.2.             By Indication

8.3.4.2.3.             By Route of Administration

8.3.4.2.4.             By Type

8.3.4.2.5.             By Age Group

8.3.4.2.6.             By End User

8.3.4.2.7.             By Distribution Channel

8.3.5.     Spain Antiviral Drugs Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Drug Class

8.3.5.2.2.             By Indication

8.3.5.2.3.             By Route of Administration

8.3.5.2.4.             By Type

8.3.5.2.5.             By Age Group

8.3.5.2.6.             By End User

8.3.5.2.7.             By Distribution Channel

9.    North America Antiviral Drugs Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Drug Class

9.2.2.     By Indication

9.2.3.     By Route of Administration

9.2.4.     By Type

9.2.5.     By Age Group

9.2.6.     By End User

9.2.7.     By Distribution Channel

9.2.8.     By Country

9.3.  North America: Country Analysis

9.3.1.     United States Antiviral Drugs Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Drug Class

9.3.1.2.2.             By Indication

9.3.1.2.3.             By Route of Administration

9.3.1.2.4.             By Type

9.3.1.2.5.             By Age Group

9.3.1.2.6.             By End User

9.3.1.2.7.             By Distribution Channel

9.3.2.     Mexico Antiviral Drugs Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Drug Class

9.3.2.2.2.             By Indication

9.3.2.2.3.             By Route of Administration

9.3.2.2.4.             By Type

9.3.2.2.5.             By Age Group

9.3.2.2.6.             By End User

9.3.2.2.7.             By Distribution Channel

9.3.3.     Canada Antiviral Drugs Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Drug Class

9.3.3.2.2.             By Indication

9.3.3.2.3.             By Route of Administration

9.3.3.2.4.             By Type

9.3.3.2.5.             By Age Group

9.3.3.2.6.             By End User

9.3.3.2.7.             By Distribution Channel

10.  South America Antiviral Drugs Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Drug Class

10.2.2.  By Indication

10.2.3.  By Route of Administration

10.2.4.  By Type

10.2.5.  By Age Group

10.2.6.  By End User

10.2.7.  By Distribution Channel

10.2.8.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Antiviral Drugs Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Drug Class

10.3.1.2.2.           By Indication

10.3.1.2.3.           By Route of Administration

10.3.1.2.4.           By Type

10.3.1.2.5.           By Age Group

10.3.1.2.6.           By End User

10.3.1.2.7.           By Distribution Channel

10.3.2.  Argentina Antiviral Drugs Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Drug Class

10.3.2.2.2.           By Indication

10.3.2.2.3.           By Route of Administration

10.3.2.2.4.           By Type

10.3.2.2.5.           By Age Group

10.3.2.2.6.           By End User

10.3.2.2.7.           By Distribution Channel

10.3.3.  Colombia Antiviral Drugs Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Drug Class

10.3.3.2.2.           By Indication

10.3.3.2.3.           By Route of Administration

10.3.3.2.4.           By Type

10.3.3.2.5.           By Age Group

10.3.3.2.6.           By End User

10.3.3.2.7.           By Distribution Channel

11.  Middle East and Africa Antiviral Drugs Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Drug Class

11.2.2.  By Indication

11.2.3.  By Route of Administration

11.2.4.  By Type

11.2.5.  By Age Group

11.2.6.  By End User

11.2.7.  By Distribution Channel

11.2.8.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Antiviral Drugs Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Drug Class

11.3.1.2.2.           By Indication

11.3.1.2.3.           By Route of Administration

11.3.1.2.4.           By Type

11.3.1.2.5.           By Age Group

11.3.1.2.6.           By End User

11.3.1.2.7.           By Distribution Channel

11.3.2.  Saudi Arabia Antiviral Drugs Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Drug Class

11.3.2.2.2.           By Indication

11.3.2.2.3.           By Route of Administration

11.3.2.2.4.           By Type

11.3.2.2.5.           By Age Group

11.3.2.2.6.           By End User

11.3.2.2.7.           By Distribution Channel

11.3.3.  UAE Antiviral Drugs Market Outlook

11.3.3.1.      Market Size & Forecast